Ce diaporama a bien été signalé.
Le téléchargement de votre SlideShare est en cours. ×

Driving Digitalization in Biopharma R&D

Plus De Contenu Connexe

Driving Digitalization in Biopharma R&D

  1. 1. DRIVING DIGITALIZATION IN BIOPHARMA R&D Which direction should you take?
  2. 2. About the survey Accenture conducted a survey to understand the state of digitalization that included responses from 250 executives from North America, EMEA, and Asia representing diverse R&D organizations within biopharmaceutical companies. Company HQ & Respondent Location: Revenue of Respondent Organization: The survey respondents were R&D executives, with one third holding a Vice President, Senior Vice President or Executive Vice President title.
  3. 3. Driving Digitalization In an era of New Science, the survey focused on these areas related to the progress of implementation and adoption of digital technologies in biopharma R&D: Strategy Value Progress Barriers to adoption
  4. 4. Four findings emerged that provide insight into the current state of digitalization in the biopharma industry Checking the signposts Navigating the curves Companies can overcome operational and cultural impediments to move digitalization forward Moving toward a clear destination The industry sees the value of digital Tapping the brakes Risk-aversion is an impediment to progress Staying in one lane While digital pockets exist, digitalization at scale is elusive
  5. 5. 72% of companies believe digital will drive success in achieving strategic imperatives Up 200% Moving toward a clear destination: Digital is increasingly perceived as an enabler to achieve R&D imperatives According to respondents, digital will help achieve the following three imperatives: 85% Be more focused on patient outcomes 72% Revitalize the pipeline by enabling breakthrough science 75% Improve R&D productivity from 2016
  6. 6. Moving toward a clear destination: Digital is increasingly perceived as an enabler to achieve R&D imperatives In order to achieve the full value of digitalization at scale, there was a strong response to these specific opportunities: 88% of respondents said using real world data (RWD) across R&D would enhance decision-making 79% reported that open collaboration with other companies would improve R&D outcomes 77% believed the ability to better manage data across the enterprise could deliver measurable business value 68% felt that improved digitalization would improve the patient experience in clinical trials
  7. 7. Two Thirds of respondents believe an aversion to risk is preventing them from fully embracing digitalization. In companies with market caps above $10B, that number jumps to Tapping the brakes: Risk-aversion is an impediment to progress As noted, 72% of companies believe digital will drive success in achieving strategic imperatives… 72% 36% of companies are adopting digital as a key strategy in R&D … yet only 75%
  8. 8. Tapping the brakes: Risk-aversion is an impediment to progress The industry’s hesitation to take the “foot off the brakes” is slowing the adoption of digital capabilities and translating into activity that does not follow a clear vision or roadmap 50% of the respondents are only “exploring” how digital technologies can enable R&D 15% continue to take a “wait-and-see” attitude, observing how others are benefiting from digital before embarking on their own exploration
  9. 9. A cautious and incremental approach has resulted in widespread digital pilots, proofs-of-concept, and minimum viable products (MVP) Staying in one lane: Digitalization is happening in silos R&D functions will often focus on select digital use cases to meet a need at a point in time, all without an eye towards repeatability and extensibility 81% say there is strong alignment on the importance of digitalization strategy across R&D yet 88% report that digitalization is happening in silos
  10. 10. Staying in one lane: Digitalization is happening in silos Globally, less than half of respondents say that digitalization is being driven at an enterprise-wide level by the organization’s C-suite leaders 41% Agreed with that statement Outside of North America, only 60% Agreed that digitalization is being driven across the enterprise In North America,
  11. 11. Top 3 barriers to digitalization: ▌Ability to measure value ▌Ability to invest ▌Access to talent Navigating the curves: Companies can overcome the barriers In addition to risk aversion, our research found several operational and cultural barriers to the adoption of digitalization
  12. 12. Navigating the curves: Companies can overcome the barriers Ability to measure value Ability to invest 60% do not have the budget available to fully realize our plans for digitalization Access to talent are struggling to measure the success of digitalization so far 60% 46% say there is a lack of IT resources to implement digital technologies 34% not able to attract the right skills and talent
  13. 13. Will these companies stay on their current path of experimentation, or will they find a path to accelerate to digitalization at scale? Industry at a crossroads: stay on course or move to scale?
  14. 14. How to accelerate R&D digitalization: Make it a strategic priority Create a goal for digitalization tied to strategic objectives and aligned to an enterprise-wide digital strategy 1 2 Assess & address the full scope of change Review the company’s appetite for investment and cultural change to choose the order and pace of transformation 3 Makeitateam sport&break downsilos Move beyond digital pilots and experiments through collaboration, cross-functional data strategies, and data sharing platforms 4 Learn how to fail fast Establish a robust digital use-case pipeline that allows for abandoning losers and quickly picking winners to progress from rapid design sprints into prototyping 5 Prove the value of your investments Determine how you will measure success and use those metrics to build a case for sustainable digital investment
  15. 15. For more information, please contact: TOM LEHMANN Managing Director Accenture Life Sciences thomas.w.lehmann@accenture.com KATIE MIINCH Senior Manager Accenture Life Sciences katie.miinch@accenture.com PETRA JANTZER Managing Director Accenture Life Sciences petra.jantzer@accenture.com Follow us at @AccentureLifSci Connect with us on LinkedIn Visit us at: accenture.com/LifeSciences accenture.com/R-DSolutions accenture.com/LifeSciencesBlog

×